Table 2.
Demographic, clinical and laboratory characteristics of 14 kidney transplant recipients.
| N. | Age | Gender | Total Lymphocytes Cells/mcL | CD3+ Cells/mcL (%) | CD3+ CD4+ Cells/mcL (%) | CD3+ CD8+ Cells/mcL (%) | CD19+ Cells/mcL (%) | CD3-CD16+CD56+ Cells/mcL (%) | Transplant (YEARS) | Immunosoppressive Therapy | Comorbidity | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SO | 54 | M | 2249 | 1214 (53.9%) | 608 (27%) | 574 (25.5%) | 92 (4.1%) | 943 (42%) | 1 | TAC/MMF/CCS | hypertension, diabetes |
| 2 | LL | 31 | M | 1779 | 1496 (83%) | 521 (29%) | 856 (47%) | 4 (0.2%) | 279 (15%) | 14 | TAC/CCS | MGUS, hypertension |
| 3 | BLT | 43 | F | 1573 | 1079 (68%) | 538 (34%) | 530 (33%) | 205 (13%) | 289 (18%) | 2 | TAC/MMF/CCS | |
| 4 | SM | 54 | F | 2720 | 2054 (74.8%) | 1098 (40%) | 893 (32%) | 308 (11%) | 358 (13%) | 1 | TAC/MMF/CCS | hypertension, diabetes, cardiovascular disease |
| 5 | LT | 67 | F | 1353 | 1235 (91%) | 908 (67%) | 313 (23%) | 28 (2.1%) | 93 (7%) | 11 | TAC/MMF/CCS | |
| 6 | VD | 78 | M | 1381 | 872 (62%) | 692 (49%) | 170 (12%) | 173 (12%) | 336 (24%) | 16 | TAC/CCS | hypertension, diabetes, COVID-19 history |
| 7 | IC | 59 | M | 2007 | 1891 (94%) | 706 (35%) | 1101 (55%) | 74 (3.7%) | 42 (2.1%) | 10 | TAC/CCS | hypertension, diabetes |
| 8 | CF | 48 | M | 1257 | 1041 (82%) | 604 (48%) | 347 (27%) | 55 (4.4%) | 161 (13%) | 1 | TAC/MMF/CCS | hypertension, cardiovascular disease |
| 9 | SG | 64 | M | 2188 | 1667 (76%) | 538 (24%) | 1047 (47%) | 286 (13%) | 235 (11%) | 1 | TAC/MMF/CCS | HIV + |
| 10 | MG | 48 | F | 1233 | 1001 (81%) | 660 (53%) | 300 (24%) | 23 (1.8%) | 209 (17%) | 3 | TAC/MMF/CCS | MGUS, hypertension, diabetes, cardiovascular disease |
| 11 | TM | 47 | F | 1450 | 1115 (76%) | 681 (47%) | 406 (28%) | 150 (10%) | 185 (12%) | 4 | TAC/MMF/CCS | Hypertension, autoimmune thyroiditis |
| 12 | PO | 72 | M | 1853 | 1339 (72%) | 260 (14%) | 911 (49%) | 66 (3.6%) | 448 (24%) | 2 | TAC/m-TORi/CCS | hypertension, diabetes |
| 13 | PM | 66 | M | 2446 | 2198 (89%) | 481 (19%) | 1581 (64%) | 110 (4%) | 138 (5%) | 4 | TAC/MMF/CCS | BPCO, hypertension |
| 14 | MB | 56 | M | 2652 | 1895 871%) | 1304 (49%) | 552 (21%) | 179 (7%) | 578 (22%) | 2 | TAC/MMF/CCS | MGUS, hypertension, diabetes |
tacrolimus (TAC)/mycophenolate mofetil (MMF)/corticosteroids (CCS)/inhibitors of Mammalian Target of Rapamycin (mTORi).